Family Group
Buprenorphine elicits the same feelings of euphoria and respiratory depression as opioids, being an opioid partial agonist. However, the effects of buprenorphine are not as strong as those of full-spectrum drugs like heroin and methadone. Buprenorphine-naloxone is the generic name (Sud et al., 2022). It is frequently used with naloxone, found in Suboxone, to avoid abuse. Understanding that abusing Suboxone will not provide pleasure and will instead create an abrupt withdrawal will help prevent both pharmaceutical abuse and overdose.
History
In 1966, British chemist John Lewis of Reckitt and Colman, a home goods firm, discovered buprenorphine while working on developing analgesics. Later, he assisted in providing buprenorphine to the ARC for study through Reckitt and Colman. In 1978, the UK granted licenses for injectable and sublingual formulations of buprenorphine for pain treatment (Sud et al., 2022). In the US, parenteral buprenorphine was given its approval in 1985 for managing acute or post-surgical pain. With buprenorphine authorized for medical use since the 1980s, it has been well-established as a medication for opioid addiction treatment.
Legitimate Reasons
In medication-assisted treatment (MAT) programs for opioid use disorder (OUD), buprenorphine is primarily utilized. For opioid use disorder, buprenorphine is an efficient maintenance therapy (Weicker et al., 2019). Relapse rates are significant when buprenorphine is used as a medically supervised withdrawal drug without maintenance medicine to support abstinence. It assists in lessening cravings and withdrawal symptoms so that people may concentrate on their rehabilitation. Patients may focus on their treatment rather than experiencing uncomfortable withdrawal symptoms when using buprenorphine replacement therapy. The medication shows promise in treating opioid dependency by reducing cravings and improving quality of life in general while undergoing addiction therapy.
Limitations
Buprenorphine’s tendency for abuse makes it a restricted drug. Those who are addicted to modest doses of opiates or those who are just beginning to experience withdrawal symptoms are more likely to misuse buprenorphine because of its ceiling effect and capacity to precipitate withdrawal symptoms if taken in large dosages (Weicker et al., 2019). Providers must complete specialized training to write prescriptions since they are strictly controlled. The majority of doctors in general care and addiction specialists who were polled in the years after the introduction of buprenorphine described a key obstacle as their lack of experience, education, training, and understanding in prescribing buprenorphine.
Set
A set describes a person’s mentality or psychological condition. A person’s or a group’s ingrained beliefs about philosophy, culture, values, worldview, outlook on life, and temperament are called their mentality. It might also stem from someone’s beliefs about what life is all about or their worldview. According to some academics, people can have more than one kind of attitude (Weicker et al., 2019).
A supportive set in the context of buprenorphine treatment entails the patient’s commitment to recovery, willingness to participate in therapy, and drive to refrain from opiate usage. Buprenorphine decreases pain perception by intercepting the signals that nerves are supposed to convey to the brain and body about pain. Buprenorphine alleviates symptoms of abstinence and harmful behaviors related to illicit opioid use by generating a safer opioid substitute. A willingness to engage in unpleasant conversations, experience emotional catharsis, disclose oneself, attend regular sessions, and exhibit other characteristics can all indicate positive engagement in therapy.
Setting
The setting may be vital, as it can shape character interactions and narrative development. It includes environmental, social, and physical aspects. The healthcare community encompasses institutions and providers such as acute units, hospitals, urgent care centers, rehabilitation centers, nursing homes, other long-term care facilities, and specialized outpatient services (Weicker et al., 2019). An epidemiologic inquiry may concentrate on specific sites or services within each context. Secure housing, quick access to medical professionals, and a supportive environment free of drug-use signals are all necessary elements of a buprenorphine treatment setting.
Pharmacokinetics
Buprenorphine operates both as a partial agonist and as an antagonist for mu-and kappa-opioid receptors. It has less intrinsic activity but higher receptor affinity for the mu-opioid receptor than does the spread full mu-opioid agonist such as heroin or oxycodone. The medicine is administered sublingually or under the tongue. It passes quickly through the mucosal and gastric membranes. But if taken orally, buprenorphine has a relatively limited oral bioavailability,10% of the intravenous route, because of its significant first-pass metabolism (Weicker et al., 2019).
One of the unique features is that the drug has a long-acting half-life; that is, fewer dosages are needed. It is known that the half-life of buprenorphine ranges from 25 to 70 hours when administered sublingually, with a mean half-life of 38 hours (Weicker et al., 2019). The CYP3A4 enzyme is inhibited when drugs that strongly inhibit it are taken, which raises buprenorphine levels.
Pharmacodynamics
Buprenorphine is similar to other opioids in its ability to attach to the opioid receptors of the brain. This receptor has a lower affinity for it, so the chance of euphoria and respiratory depression is even lower. Although substances work with buprenorphine in a limited way as compared with full-spectrum drugs such as heroin and methadone, they are still promising options for opiate substitution treatment (Weicker et al., 2019). It minimizes the desire and problematic symptoms, which are used for stable minds of people who are affected by opioid addiction. Buprenorphine and methadone, when given and monitored closely, have been demonstrated to lessen physiological cravings, return everyday brain chemistry and body functions, and avoid the euphoric effects of other opioids when taken together.
Administration and Absorption Rates
Treatment for OUD involves the use of the drug buprenorphine. Sublingual tablets, films, implants, buccal films, and extended-release injections are some available formulations. Buprenorphine swiftly enters the bloodstream through the sublingual mucosa.
Its bioavailability is notably high when delivered intravenously or subcutaneously but decreases when administered sublingually or buccally (Weicker et al., 2019). Orally administered buprenorphine is inadequate due to low bioavailability. Consequently, it is available as a sublingual pill, bypassing the oral mucosa and entering the systemic circulation directly.
Distribution and Metabolism
Buprenorphine is widely distributed throughout the body and is highly protein-bound. Its high lipophilicity allows it to permeate widely and to pass swiftly through the blood-brain barrier. Through intravenous administration, the distribution of the drug volume is estimated to be from 188 to 335 L (Weicker et al., 2019).
The liver remains the principal organ where buprenorphine is enzymatically converted. Primarily due to hepatic metabolism, buprenorphine is best administered sublingually, buccally, subcutaneously, or by depot injection. Buprenorphine’s metabolism is primarily mediated by hepatic CYP3A4, which catalyzes its conversion to its active metabolite, norbuprenorphine.
Excretion and Overdose Potential
Buprenorphine has a relatively long terminal elimination half-life, with observed values typically ranging from 3 to 44 hours. A considerable proportion of buprenorphine intake is excreted through feces, and about 10-30% of that dose is excreted through urine (McGee et al., 2023). Buprenorphine is an opioid partial agonist of μ-receptor. On the other hand, it can be misused by consumption and respiratory arrest as well. In cases where it is administered with other CNS depressants like alcohol, benzodiazepines, some antidepressants, antihistamines, hypnotics, and sedatives, it can cause respiratory depression that results in death, coma, or induce coma.
Undesirable or Side Effects and Community Support
Common side effects include headache, nausea, vomiting, constipation, sweating, inability to sleep, poor sleep, and physical pains. Patients on buprenorphine therapy may require support groups, counseling, and mental health services, as these interventions are crucial to resolving the fundamental causes of addiction (McGee et al., 2023). A considerable benefit of buprenorphine is that, in case of proper use, overdosing rarely happens. A doctor, after the first prescription, is given a choice to prescribe buprenorphine every other day instead of daily, since it has an extended half-life.
References
McGee, M., Chiu, K., Moineddin, R., & Sud, A. (2023). The impact of Suboxone’s market exclusivity on cost of opioid use disorder treatment. Applied Health Economics and Health Policy, 21(3), 501–510.
Sud, A., McGee, M., Mintzes, B., & Herder, M. (2022). Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada. International Journal of Drug Policy, 105.
Weicker, S. A., Hayashi, K., Grant, C., Milloy, M. J., Wood, E., & Kerr, T. (2019). Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada. Drug and alcohol dependence, 205.